Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer-Reply

Affiliations

¹ Carolina Urologic Research Center, Myrtle Beach, South Carolina.
² University of California, San Francisco.
³ Departments of Pathology and Urology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor.

Comment

Neal D Shore et al. JAMA Oncol. 2023.

. 2023 Jan 1;9(1):150-151.

doi: 10.1001/jamaoncol.2022.5249.

¹ Carolina Urologic Research Center, Myrtle Beach, South Carolina.
² University of California, San Francisco.
³ Departments of Pathology and Urology, Rogel Cancer Center, University of Michigan Medical School, Ann Arbor.

No abstract available

Comment on

Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer.
Busby D, Menon M, Tewari AK. Busby D, et al. JAMA Oncol. 2022 Nov 10. doi: 10.1001/jamaoncol.2022.5243. Online ahead of print. JAMA Oncol. 2022. PMID: 36355379 No abstract available.
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer.
Klotz L. Klotz L. JAMA Oncol. 2022 Nov 10. doi: 10.1001/jamaoncol.2022.5246. Online ahead of print. JAMA Oncol. 2022. PMID: 36355383 No abstract available.
Antiandrogen Treatment vs Active Surveillance for Patients With Prostate Cancer.
Halthore AN, Andriole GL, Goldstein M. Halthore AN, et al. JAMA Oncol. 2022 Nov 10. doi: 10.1001/jamaoncol.2022.5240. Online ahead of print. JAMA Oncol. 2022. PMID: 36355389 No abstract available.